Across TCGA pan-cancer cohorts, PTP4A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTP4A2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTP4A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTP4A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where PTP4A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.652	1.000	.008	35	view →
LUAD	DFS	Median	All	0.886	0.479	.002	15	view →
PDAC	OS	Median	II,III,IV	0.444	0.281	.016	4	view →
LSCC	DFS	Quartile	II,III,IV	0.775	1.000	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PTP4A2 tumor-vs-normal RNA expression · all PTP4A2 data types